Effects of Tislelizumab Combined with Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma
Objective To discuss the clinical effects of tislelizumab combined with lenvatinib on glutamic-pyruvic transaminase/glutamic-oxaloacetic transaminase(GPT/GOT)ratio,albumin/globulin ratio(ALB/GLB)and survival time in patients with unresectable hepatocellular carcinoma.Methods Ninety-two patients with unresectable hepatocellular carcinoma in the hospital from January 2021 to October 2022 were enrolled,and divided into two groups according to the treatment methods.Control group(44 cases)received transcatheter arterial chemoembolization(TACE),based on this,combined group(48 cases)received tislelizumab combined with lenvatinib.The general data,GPT,GOT,ALB,GLB and survival rate was compared.Results There was no statistically difference in general information between the two groups of patients(P＞0.05).There was no statistically difference in GPT,GOT,GPT/GOT,ALB,GLB and ALB/GLB between the two groups before treatment(P＞0.05).After treatment,both groups showed an increase in GPT,GOT,GPT/GOT,ALB and ALB/GLB,while GLB decreased,and GPT,GOT and GLB in the combined group were lower than those in the control group,GPT/GOT,ALB and ALB/GLB were higher than those in the control group(P＜0.05).After a 6-month follow-up,it was found that there was no statistically difference in survival rates between the two groups at 1 month and 3 months(P＞0.05).At 6 months,the survival rate of the combined group was higher than that of the control group(P＜0.05).Conclusion Tislelizumab combined with lenvatinib for patients with unresectable hepatocellular carcinoma can effectively alleviate the damage to the liver function,attenuate the body inflammation reaction and prolong the survival time in patients.
NETL
NSTL
万方数据
